What Is Graft-Versus-Host Disease and How Is It Treated?

When the Cure Attacks the Patient

Bone marrow and stem cell transplants save thousands of lives each year, offering a path to recovery for patients with leukemia, lymphoma, aplastic anemia, and other blood disorders. But they carry a profound biological paradox: the very immune cells that make the donor's graft so powerful can turn against the patient's own body. This complication is called graft-versus-host disease, or GVHD — and it remains one of the most challenging problems in modern medicine.

What Causes GVHD?

When a patient receives an allogeneic transplant — meaning donor cells from another person — those donor T cells enter a foreign environment. Despite careful tissue matching between donor and recipient, subtle differences in proteins on the surface of cells trigger an immune response. The donor's T cells interpret the recipient's tissues as threats and mount an attack.

According to the Cleveland Clinic, GVHD affects between 30% and 70% of allogeneic transplant recipients, depending on the degree of tissue mismatch, the patient's age, and the type of conditioning regimen used. It is the leading cause of non-relapse mortality after transplant — meaning it kills patients whose cancer may have been cured.

Acute vs. Chronic GVHD

Doctors recognize two distinct forms of the disease. Acute GVHD typically strikes within the first 100 days after transplantation. It primarily targets three organ systems:

• Skin — rashes, blistering, redness
• Liver — elevated enzymes, jaundice
• Gastrointestinal tract — severe diarrhea, nausea, cramping

Chronic GVHD, which can develop at any point after 100 days, behaves more like an autoimmune disorder. It can affect the mouth, eyes, lungs, muscles, joints, and connective tissue, causing symptoms resembling scleroderma or lupus. Chronic GVHD affects roughly 40–50% of allogeneic transplant recipients, according to the National Institutes of Health, and can persist for years.

Standard Prevention and Treatment

Preventing GVHD begins before the transplant. Patients receive immunosuppressive drugs — typically a combination of tacrolimus (a calcineurin inhibitor) and methotrexate — to blunt the donor T cells' response. This regimen has been the backbone of GVHD prophylaxis since the 1980s.

When GVHD develops anyway, the first line of treatment is corticosteroids such as methylprednisolone or prednisone. About half of acute GVHD cases respond to steroids. Those that do not — so-called steroid-refractory GVHD — are significantly harder to manage and carry a much higher mortality risk, as noted by Cancer Research UK.

Newer Drugs: JAK Inhibitors and Beyond

The past decade brought a wave of FDA-approved therapies for steroid-refractory GVHD. Ruxolitinib, a JAK1/JAK2 inhibitor, has become the most evidence-backed option for both acute and chronic forms, with the REACH3 clinical trial showing significantly higher response rates than best available therapy. Belumosudil, a ROCK2 inhibitor, is another approved agent showing overall response rates of around 65–75% in clinical trials.

Emerging research, published in Bone Marrow Transplantation, points to triple-drug combinations — including ruxolitinib, belumosudil, and the experimental agent axatilimab — as potentially effective in treatment-refractory cases.

The Promise of Regulatory T Cells

One of the most exciting frontiers is regulatory T cell (Treg) therapy. Tregs are a specialized subset of immune cells that naturally suppress excessive immune responses. Scientists have developed methods to isolate, expand, and infuse donor Tregs into transplant patients to prevent GVHD before it starts. Early-phase trials have reported acute grade 3–4 GVHD rates as low as 7%, compared with typical rates of 15–25% — a dramatic improvement. Unlike blunt immunosuppression, Treg therapy aims to restore tolerance, training the immune system to coexist with the host rather than suppressing it entirely.

Why GVHD Research Matters

GVHD is not just a transplant complication — it is a window into fundamental questions about immune tolerance, autoimmunity, and how the body distinguishes self from non-self. Every advance in GVHD treatment also deepens our understanding of autoimmune conditions like multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.

As transplant volumes rise globally and indications expand to older patients and less closely matched donors, solving GVHD becomes ever more urgent. The field is moving from blunt immunosuppression toward precision immune engineering — and the results, for patients who once had few options, are beginning to show.